About: Development of therapeutic antibodies for the treatment of diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of therapeutic antibodies for the treatment of diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development of therapeutic antibodies for the treatment of diseases
Creator	Liu, I-Ju Wu, Han-Chung Hwang, Yu-Chyi Lee, Chi-Chiu Li, Hsin-Jung Lu, Ruei-Min Tsai, Han-Zen
Source	Medline; PMC
abstract	It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved. Current antibody drugs have increasingly fewer adverse effects due to their high specificity. As a result, therapeutic antibodies have become the predominant class of new drugs developed in recent years. Over the past five years, antibodies have become the best-selling drugs in the pharmaceutical market, and in 2018, eight of the top ten bestselling drugs worldwide were biologics. The global therapeutic monoclonal antibody market was valued at approximately US$115.2 billion in 2018 and is expected to generate revenue of $150 billion by the end of 2019 and $300 billion by 2025. Thus, the market for therapeutic antibody drugs has experienced explosive growth as new drugs have been approved for treating various human diseases, including many cancers, autoimmune, metabolic and infectious diseases. As of December 2019, 79 therapeutic mAbs have been approved by the US FDA, but there is still significant growth potential. This review summarizes the latest market trends and outlines the preeminent antibody engineering technologies used in the development of therapeutic antibody drugs, such as humanization of monoclonal antibodies, phage display, the human antibody mouse, single B cell antibody technology, and affinity maturation. Finally, future applications and perspectives are also discussed.
has issue date	2020-01-02(xsd:dateTime)
bibo:doi	10.1186/s12929-019-0592-z
bibo:pmid	31894001
has license	cc-by
sha1sum (hex)	0d40afa4fc54a163858aeffbe43be47bf89b6f39
schema:url	https://doi.org/10.1186/s12929-019-0592-z
resource representing a document's title	Development of therapeutic antibodies for the treatment of diseases
has PubMed Central identifier	PMC6939334
has PubMed identifier	31894001
schema:publication	J Biomed Sci
resource representing a document's body	covid:0d40afa4fc54a163858aeffbe43be47bf89b6f39#body_text
is schema:about of	named entity 'United States' named entity 'antibody engineering' named entity 'This' named entity 'high' named entity 'summarizes' named entity 'potential' named entity 'developed' named entity 'top' named entity 'diseases' named entity 'antibody' named entity 'adverse effects' named entity 'autoimmune' named entity 'US FDA' named entity 'biologics' named entity 'antibody' named entity 'antibody engineering' named entity 'infectious diseases' named entity 'mAbs' named entity 'drugs' named entity 'mutation' named entity 'constant region' named entity 'immunogenic' named entity 'infectious diseases' named entity 'Antibody' named entity 'drug development' named entity 'therapeutic antibodies' named entity 'lung' named entity 'antibodies' named entity 'somatic hypermutation' named entity 'antibodies' named entity 'antibody' named entity 'IgG' named entity 'anti-HIV' named entity 'rheumatoid arthritis' named entity 'helper T cells' named entity 'CALCRL' named entity 'mAb' named entity 'IgG2' named entity 'plasma kallikrein' named entity 'Bristol-Myers Squibb' named entity 'murine' named entity 'Phase III' named entity 'antibody' named entity 'antibody-dependent cellular cytotoxicity' named entity 'cell-based' named entity 'US FDA' named entity 'peptides' named entity 'ramucirumab' named entity 'epidermal carcinoma' named entity 'high affinity' named entity 'N-hydroxysuccinimide' named entity 'humanized antibodies' named entity 'skin cell' named entity 'US FDA' named entity 'cell growth' named entity 'T-cell activation' named entity 'scFv' named entity 'antigen' named entity 'genome' named entity 'ADA' named entity 'Fab' named entity 'VEGFR2' named entity 'Humira' named entity 'CFH' named entity 'antibody' named entity 'SLE' named entity 'bevacizumab' named entity 'Phase II' named entity 'mAbs' named entity 'human disease' named entity 'therapeutic antibodies' named entity 'clinical trials' named entity 'Phase II' named entity 'PD-1' named entity 'antigen'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software